BioCanada
Filter News
Found 36,053 articles
-
American Aires Announces Agreement with William Morris Endeavor Entertainment
3/18/2024
American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) ("Aires" or the "Company"), a pioneer in cutting-edge technology designed to protect against electromagnetic radiation and optimize human health, is excited to announce a strategic partnership with William Morris Endeavor Entertainment, LLC ("WME"), a titan in entertainment, sports, and fashion.
-
Sona Nanotech Announces Filing of Provisional Patent Application
3/18/2024
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, "ENDOSCOPE WITH EMR OPTICAL FIBER AND THERMAL SENSOR FOR PHOTOTHERMAL THERAPY".
-
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
3/18/2024
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update.
-
Pharmascience Canada Launches an Extension to its New Methotrexate Product Line: pms-METHOTREXATE INJECTION 50mg/ml
3/15/2024
Pharmascience Canada is proud to announce the launch of pms- METHOTREXATE INJECTION (methotrexate injection) 50 mg/ml, a drug indicated for the treatment of psoriasis, psoriatic arthritis and rheumatoid arthritis in adults aged 18 to 65 with severe disabling conditions, when other treatments do not work.
-
NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2023 RESULTS
3/15/2024
NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three months and year ended December 31, 2023.
-
BIMZELX (bimekizumab) Now Approved for Adults with Active Psoriatic Arthritis and for Adults with Axial Spondyloarthritis
3/14/2024
Today, UCB Canada Inc. is pleased to announce that BIMZELX® (bimekizumab injection) has received authorization from Health Canada for two new indications.
-
Cosm Medical Achieves FDA Clearance for Gynethotics™ Pessaries, Pioneering the future of personalized pelvic care
3/14/2024
Cosm Medical proudly announces FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients.
-
Microbix’s Clot-Buster Drug Project Advances
3/14/2024
Microbix Biosystems Inc. announces that its funding and commercialization partner, Sequel Pharma, LLC, has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization for production of the active ingredient of Kinlytic® urokinase, a biologic drug for dissolving blood clots.
-
IBEX Files Addendum to Management Proxy Circular for Sale of the Company at $1.45 Per Share
3/14/2024
IBEX Technologies Inc. announces that it has filed an addendum to its management proxy circular dated February 23, 2024 for the annual and special meeting of shareholders to be held in Montreal, Québec on April 3, 2024.
-
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
3/14/2024
IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.
-
BioHarvest Sciences to Participate in Benzinga Virtual Healthcare Summit 2024 on March 20, 2024
3/14/2024
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform
-
Crescita Reports Q4 and Fiscal 2023 Results
3/13/2024
Crescita Therapeutics Inc., a growth-oriented, innovation-driven Canadian commercial dermatology company, reported its financial results for the fourth quarter and fiscal year ended December 31, 2023.
-
BioNxt Reports Successful Results From ODF Cladribine PK Study
3/13/2024
BioNxt Solutions Inc. is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis has been completed and results received by the Company.
-
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
3/13/2024
MedMira Inc. announces the receipt of a Canadian patent patent for its new innovative and quantitative test system.
-
Allumiqs and Prolytix form strategic partnership to accelerate drug discovery and development
3/13/2024
Allumiqs and Prolytix, announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines.
-
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
3/13/2024
Intellipharmaceutics International Inc. announces its listing on NEX, a separate board of the TSX Venture Exchange.
-
BioHarvest Sciences Announces New Strategic Hires for CDMO Services Business Unit
3/13/2024
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 13, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the appointment of two senior hires in the areas of business development and science to spearhead key initiatives as part of the Company's recently launched CDMO Services Business Unit.
-
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
3/13/2024
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023.
-
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
3/13/2024
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company") announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.
-
Revive Therapeutics Provides Corporate Update
3/12/2024
Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.